• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Anzemet (dolasetron mesylate)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

September 2013

Summary View

changes: remove all information for the prevention of postoperative nausea and vomiting based on current guidelines regarding the administration of oral Anzemet prior to surgery in the following sections:

PRECAUTIONS

Drug Interactions
Geriatric Use

ADVERSE REACTIONS